HYDELTRA-TBA Drug Patent Profile
Which patents cover Hydeltra-tba, and what generic alternatives are available?
Hydeltra-tba is a drug marketed by Merck and is included in one NDA.
The generic ingredient in HYDELTRA-TBA is prednisolone tebutate. There is one drug master file entry for this compound. Additional details are available on the prednisolone tebutate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for HYDELTRA-TBA?
- What are the global sales for HYDELTRA-TBA?
- What is Average Wholesale Price for HYDELTRA-TBA?
Summary for HYDELTRA-TBA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 43 |
| Clinical Trials: | 10 |
| Patent Applications: | 2,306 |
| DailyMed Link: | HYDELTRA-TBA at DailyMed |
Recent Clinical Trials for HYDELTRA-TBA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Children's Oncology Group | Phase 2 |
| Children's Oncology Group | Phase 1/Phase 2 |
| National Cancer Institute (NCI) | Phase 1/Phase 2 |
US Patents and Regulatory Information for HYDELTRA-TBA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | HYDELTRA-TBA | prednisolone tebutate | INJECTABLE;INJECTION | 010562-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
